ALK and non-small cell lung carcinoma: CROWN, a phase 3 clinical trial evaluating ALK-positive NSCLC patients, showed improved 12-month PFS and ORR with lorlatinib compared to crizotinib (80% vs. 35%; 76% vs. 58%, respectively).